Trading Update

RNS Number : 9864B

Alliance Pharma PLC

05 November 2009

 



For immediate release

5 November 2009

ALLIANCE PHARMA PLC

("Alliance" or "the Company")

Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to report that trading continues to be very strong.

Sales in the nine months ended 30 September 2009 were £21.4m, up 44% from the £14.9m achieved in the same period in 2008, reflecting the positive sales trends reported at the time of the Company's interim results.  Sales by Alliance of Buccastem® and Timodine®, the two brands acquired by the Company in August 2009, have been in line with management's expectations since their acquisition.

If the recent strong trading performance continues for the remainder of the year, the Board expects the Group's profit before tax for 2009 to significantly exceed its previous expectations.

The Company intends to provide a further trading update for the full year in January 2010.

For further information: 

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney

Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 37 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

TSTFSDFWLSUSEFF